microsoft office online training
microsoft office online training with http://www.mdnewscast.net

microsoft office online training

Medical Newscast

News for 12-Jul-20

Source: MedicineNet High Blood Pressure General
Normal Blood Pressure in Clinic May Mask Hypertension

Source: MedicineNet Diabetes General
glipizide and metformin (Metaglip has been discontinued in the US)

Source: MedicineNet Diabetes General
Chemo More Damaging to Hearts of Diabetics: Study

Source: MedicineNet High Blood Pressure General
High Blood Pressure Might Affect Some Kids' Thinking Ability

Source: MedicineNet Diabetes General
Health Tip: Creating an Insulin Routine

Source: MedicineNet Diabetes General
Daily Can of Soda Boosts Odds for Prediabetes, Study Finds

Source: MedicineNet High Blood Pressure General
Sharp Drop in Blood Pressure After Rx May Be Risky for Some Heart Patients

Source: MedicineNet High Blood Pressure General
Study Finds Worrisome Heart Effects Among Some Football Players

Source: MedicineNet Diabetes General
Jardiance (empagliflozin)

Source: MedicineNet Diabetes General
Low Blood Sugar Linked to Death Risk for Hospital Patients

Search the Web
iqpc
microsoft office online training
free online linux training
online ccna training
online drivers training
autocad training online
online training resources
quickbooks online training
six sigma online training
uk online training

The Best microsoft office online training website

All the microsoft office online training information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best microsoft office online training site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
microsoft office online training.

microsoft office online training

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

Use a Secure Browser when shopping for microsoft office online training. Your browser should comply with industry security standards, such as Secure Sockets Layer (SSL). These standards scramble the purchase information you send over the Internet, helping to secure your transaction. When you enter the microsoft office online training secure shopping environment you will see the URL prefix https:// instead of http://

If you pay for microsoft office online training by credit or charge card online, your transaction will be protected by legislation. Under these laws, consumers have the right to dispute microsoft office online training charges under certain circumstances and temporarily withhold payment while the creditor is investigating them. In the event of unauthorized use of your credit or charge card, you are generally held liable only for the first $50 in charges. Some companies offer an online shopping guarantee that ensures you will not be held responsible for any unauthorized charges made online.

microsoft office online training
free online linux training
online ccna training
online drivers training
autocad training online
online training resources
quickbooks online training
six sigma online training
uk online training
microsoft training online
online training excel
online training manuals
drivers training online
free online mcse training
net training online
online education and training
online training sites
paralegal training online
perl online training
sears online training
online business training
real estate training online
crystal reports online training
online training companies
online xml training
free online training course
online electronics training
online medical training
online medical transcription training
online web design training
software training online
unix training online
weight training online
fitness training online
online career training
online courses
online learning
online tutorial
online classes
courses online
tutorial online
management conference
classes online
learning online
online certification
certification online
3 button
conference management
online trainer
trainer online
conference manager
iir
ssp
institute for international research
service provider
service providers
marcus evans
trainers online
iqpc

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
Meetings On The Net | Talk On The Net | Affordable Used Cars | Medical Meetings | Take Your Meds

Medical Meetings On The Net   Medical Newscast   Kids Meet